|
Fri, 05/17/2024 - 00:03 |
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations |
|
Mon, 03/14/2022 - 14:11 |
Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees |
|
Thu, 12/30/2021 - 12:40 |
Teva Statement Following New York Jury Ruling in Opioids Trial |
|
Mon, 11/01/2021 - 14:19 |
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia |
|
Tue, 10/26/2021 - 21:59 |
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes |
|
Thu, 08/12/2021 - 17:19 |
Showcasing Tevas Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY (fremanezumab-vfrm) Injection at the International Headache Society and European Headache... |
|
Wed, 07/21/2021 - 03:38 |
Teva Announces Changes to Executive Management Team |
|
Tue, 06/09/2020 - 04:34 |
Teva Announces Virtual 2020 Annual Meeting of Shareholders |
|
Mon, 05/04/2020 - 11:08 |
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan (rituximab) Available in the United States for This Indication |
|
Fri, 05/01/2020 - 09:45 |
New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology |
|
Mon, 04/27/2020 - 11:38 |
Teva Announces U.S. Launch of Autoinjector for AJOVY (fremanezumab-vfrm) Injection |
|
Thu, 03/19/2020 - 20:58 |
Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide |
|
Mon, 03/16/2020 - 12:54 |
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA (trastuzumab-pkrb) for Injection |
|
Thu, 03/12/2020 - 07:44 |
Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY (fremanezumab) |
|
Thu, 03/12/2020 - 01:22 |
Positive Empfehlung des NICE fur die erste, gegen das CGRP gerichtete Migranetherapie: AJOVY (Fremanezumab) |
|
Thu, 03/12/2020 - 01:12 |
Avis favorable de l'Institut national pour l'excellence clinique (NICE) pour le premier traitement anti-PRGC de la migraine : AJOVY (fremanezumab) |
|
Mon, 02/24/2020 - 02:20 |
Teva Announces FDA Approval of ArmonAir Digihaler (fluticasone propionate) Inhalation Powder |
|
Wed, 02/19/2020 - 05:06 |
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint |
|
Wed, 02/12/2020 - 04:47 |
New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion |
|
Sun, 01/12/2020 - 19:32 |
Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference |
|
Tue, 12/31/2019 - 11:14 |
China Approves AUSTEDO For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults |
|
Mon, 11/25/2019 - 12:07 |
Teva and the Weizmann Institute of Science enter into collaboration to identify the next generation of innovative antibodies for cancer treatment |
|
Mon, 11/25/2019 - 12:01 |
Teva and Tel Aviv University sign a collaboration agreement for innovative R&D in the fields of cancer and brain studies |
|
Mon, 11/25/2019 - 07:52 |
Pictured right to left: Dr. Hafrun Fridriksdottir, Executive Vice President, Teva R&D; Prof. Daniel Zajfman, President of the Weizmann Institute of Science. (Photo credit: Eyal Tuag) |
|
Mon, 11/25/2019 - 07:44 |
Teva Pharmaceutical Industries Ltd. |
|
Sun, 11/24/2019 - 20:44 |
Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes |
|
Fri, 11/22/2019 - 05:01 |
Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement |
|
Thu, 11/14/2019 - 05:30 |
Teva to Present New Data on AJOVY (fremanezumab-vfrm) Injection at the American Headache Societys 61st |
|
Fri, 11/08/2019 - 11:09 |
Teva Announces $1.5 Billion Debt Tender Offers |
|
Thu, 11/07/2019 - 03:44 |
Teva Announces Appointment of New Chief Financial Officer |
|
Wed, 10/23/2019 - 22:16 |
Teva to Present New Analyses of Fremanezumab and Country-Specific Burden of Migraine at 24th World Congress of Neurology |
|
Fri, 10/04/2019 - 04:03 |
Findings describe the efficacy and safety results of clinical trials of fremanezumab through 12 months of treatment in patients with chronic and episodic migraine |
|
Fri, 09/06/2019 - 02:25 |
Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society |
|
Mon, 07/15/2019 - 13:49 |
Teva Announces FDA Approval of AirDuo Digihaler (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder |
|
Mon, 07/15/2019 - 06:30 |
Teva Announces FDA Approval of AirDuo Digihaler (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder |
|
Thu, 07/11/2019 - 05:37 |
Teva Drives Progress to Address Pressing Global Health Challenges While Maintaining Focus on Compliance |
|
Thu, 07/11/2019 - 04:26 |
Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus |
|
Tue, 07/02/2019 - 05:22 |
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine |
|
Mon, 06/03/2019 - 15:26 |
Teva to Present New Data on AUSTEDO (deutetrabenazine) Tablets at Psych Congress 2019 |
|
Sat, 06/01/2019 - 05:23 |
Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headache Federation Congress |
|
Wed, 04/10/2019 - 13:05 |
Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy of Neurology |
|
Wed, 04/10/2019 - 08:34 |
Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neurology Annual Meeting |
|
Mon, 01/07/2019 - 16:05 |
Teva to Present at the 37th Annual J.P. Morgan Healthcare Conference |
|
Wed, 01/02/2019 - 14:45 |
Teva and Amgen Resolve Ongoing Dispute Over Tevas Generic Cinacalet HCl Product |
|
Mon, 12/31/2018 - 17:50 |
Teva Announces Launch of a Generic Version of Letairis (ambrisentan) Tablets in the United States |
|
Mon, 12/31/2018 - 17:33 |
Tevas AJOVY Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults |
|
Mon, 12/31/2018 - 16:08 |
Teva Announces Launch of a Generic Version of Ranexa (ranolazine) Extended-Release Tablets in the United States |
|
Mon, 12/31/2018 - 13:37 |
Teva Announces Launch of a Generic Version of Tracleer (bosentan) Tablets in the United States |
|
Mon, 12/31/2018 - 12:54 |
Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties |
|
Mon, 12/31/2018 - 12:49 |
Teva Announces Launch of a Generic Version of VESIcare (solifenacin succinate) Tablets in the United States |
|
Mon, 12/31/2018 - 12:00 |
Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility |
|
Mon, 12/31/2018 - 11:39 |
Teva Announces Launch of an Authorized Generic of Flector Patch (diclofenac epolamine topical patch) in the United States |
|
Mon, 12/31/2018 - 10:36 |
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache |
|
Mon, 12/31/2018 - 08:08 |
Teva Announces Launch of a Generic Version of AndroGel (testosterone gel) 1.62% CIII in the United States |
|
Mon, 12/31/2018 - 03:16 |
Company Statement: Teva Reaches Agreement with State of Oklahoma to Resolve States Claims Against the Company |
|
Mon, 12/31/2018 - 00:42 |
Teva Announces Launch of a Generic Version of EXJADE (deferasirox) Tablets For Oral Suspension in the United States |
|
Mon, 12/31/2018 - 00:36 |
Tevas COPAXONE 40mg Favorable Response from European Patent Office |
|
Sun, 12/30/2018 - 22:31 |
Teva Announces the Launch of a Generic Version of Delzicol (mesalamine) Delayed-Release Capsules in the United States |
|
Sun, 12/30/2018 - 22:08 |
Teva Announces Launch of a Generic Version of Tarceva (erlotinib) Tablets in the United States |
|
Fri, 12/21/2018 - 00:55 |
ADDING MULTIMEDIA Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder |
|
Mon, 12/17/2018 - 12:54 |
Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not Respond to Multiple Classes of Preventive Treatments |
|
Wed, 11/28/2018 - 06:49 |
Celltrion and Teva Announce FDA Approval of TRUXIMA (rituximab-abbs), a Biosimilar to RITUXAN, for Three Non-Hodgkins Lymphoma Indications |
|
Tue, 11/27/2018 - 12:13 |
Tevas Generic Version of EpiPen (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United States |
|
Tue, 11/27/2018 - 07:08 |
Tevas Generic Epinephrine Injection Now Available in Limited Quantity in the US |
|
Sat, 10/20/2018 - 23:01 |
Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel |
|
Thu, 10/11/2018 - 16:24 |
Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions |
|
Wed, 10/10/2018 - 17:07 |
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar |
|
Wed, 10/10/2018 - 16:52 |
Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis |
|
Sun, 10/07/2018 - 20:47 |
Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin |
|
Thu, 09/27/2018 - 07:09 |
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis in the United States |
|
Tue, 09/18/2018 - 03:22 |
Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement |
|
Thu, 09/13/2018 - 20:15 |
Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection |
|
Thu, 09/13/2018 - 19:55 |
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults |
|
Tue, 09/11/2018 - 20:52 |
Teva to Present at the Morgan Stanley Global Healthcare Conference |
|
Mon, 09/03/2018 - 23:55 |
Teva Announces $400 Million Debt Tender Offer |
|
Thu, 08/16/2018 - 03:55 |
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip |
|
Mon, 08/06/2018 - 06:34 |
Teva Announces Updated Indication and Vial Presentation for GRANIX (tbo-filgrastim) Injection in United States |
|
Tue, 07/17/2018 - 20:16 |
Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report |
|
Mon, 07/09/2018 - 06:41 |
Teva Announces Launch of a Generic Version of Uceris in the United States |
|
Thu, 06/28/2018 - 19:16 |
Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Societys 60th Annual Scientific Meeting |
|
Fri, 06/15/2018 - 09:49 |
Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache |
|
Wed, 05/23/2018 - 04:21 |
Teva Confirms September PDUFA Date for Fremanezumab |
|
Fri, 05/18/2018 - 14:58 |
CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association |
|
Tue, 05/15/2018 - 09:43 |
Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association |
|
Wed, 05/02/2018 - 07:20 |
Teva to Present AUSTEDO (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual Meeting |
|
Thu, 04/26/2018 - 18:40 |
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL |
|
Thu, 04/19/2018 - 07:01 |
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership |
|
Mon, 03/26/2018 - 12:01 |
Teva Announces the Launch of a Generic Version of Lialda in the United States |
|
Fri, 03/23/2018 - 13:42 |
Teva Announces the Launch of a Generic Version of ALOXI in the United States |
|
Mon, 03/12/2018 - 08:36 |
Teva to Present at the Cowen & Company 38th Annual Healthcare Conference |
|
Wed, 03/07/2018 - 13:27 |
Teva Announces Upsizing and Successful Pricing of $4.5 Billion of Senior Notes |
|
Wed, 02/28/2018 - 06:27 |
Teva Announces Launch of Offering of Senior Notes |
|
Tue, 02/20/2018 - 01:11 |
Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn in the United States |
|
Mon, 02/12/2018 - 07:17 |
Teva Announces U.S. Launch of QVAR RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol |
|
Fri, 02/09/2018 - 10:43 |
Teva Announces Launch of a Generic Version of Syprine in the United States |
|
Fri, 02/02/2018 - 08:34 |
European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application |
|
Thu, 02/01/2018 - 06:00 |
Teva Announces Completion of Global Womens Health Divestiture to CVC Capital Partners |
|
Mon, 01/22/2018 - 02:09 |
Teva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic Asthma |
|
Mon, 01/15/2018 - 00:31 |
Teva Announces U.S. FDA Approval of TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia |
|
Sun, 01/07/2018 - 23:44 |
Teva Announces Global License Agreement with Alder BioPharmaceuticals in the Field of Anti-CGRP-Based Therapy |
